NOVOLIN R
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NOVOLIN R (NOVOLIN R).
Regular insulin lowers blood glucose by promoting peripheral glucose uptake, especially in skeletal muscle and adipose tissue, and by inhibiting hepatic glucose production. It binds to insulin receptors on cell membranes, activating tyrosine kinase activity and downstream signaling pathways that regulate glucose transport and metabolism.
| Metabolism | Primarily metabolized by insulin-degrading enzyme (IDE) in the liver, kidney, and muscle. Clearance is predominantly hepatic (∼60%) and renal (∼35–40%). |
| Excretion | Renal (tubular reabsorption and metabolism). Approximately 50-80% of insulin is degraded in the liver and kidneys; the remainder is excreted in urine as metabolites and intact hormone (<1%). |
| Half-life | Intravenous: 5-10 minutes (short due to rapid distribution and degradation). Subcutaneous: 1-2 hours (terminal half-life after absorption). |
| Protein binding | <5% bound to serum proteins (primarily albumin); clinically insignificant. |
| Volume of Distribution | 0.15-0.25 L/kg; approximates extracellular fluid volume, consistent with distribution into interstitial space. |
| Bioavailability | Subcutaneous: 50-65% (due to local degradation at injection site and variable absorption). |
| Onset of Action | Intravenous: 10-30 minutes; Subcutaneous: 30-60 minutes. |
| Duration of Action | Intravenous: 30-60 minutes; Subcutaneous: 5-8 hours (longer with higher doses; duration extends due to continued absorption from depot). |
Subcutaneous: 0.5-1 unit/kg/day divided into 2-3 doses; intravenous: continuous infusion starting at 0.05-0.1 units/kg/hr adjusted based on blood glucose.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for GFR >50 mL/min; for GFR 10-50 mL/min, reduce dose by 25%; for GFR <10 mL/min, reduce dose by 50% and monitor closely. |
| Liver impairment | In Child-Pugh class A, no adjustment; class B, reduce dose by 25%; class C, reduce dose by 50% and monitor glucose frequently. |
| Pediatric use | Subcutaneous: 0.5-1 unit/kg/day in divided doses; for continuous subcutaneous insulin infusion (CSII), start with 0.2-0.5 units/kg/day, adjusted based on glucose monitoring. |
| Geriatric use | Start with lower doses (e.g., 0.3-0.5 units/kg/day) due to increased risk of hypoglycemia; titrate slowly based on glucose response and renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NOVOLIN R (NOVOLIN R).
| Breastfeeding | Insulin is excreted in breast milk in very low amounts. M/P ratio is approximately 1.0 for insulin. It is not orally bioavailable to the infant due to digestion in the gastrointestinal tract. Considered compatible with breastfeeding. |
| Teratogenic Risk | Insulin does not cross the placenta in significant amounts. No increased risk of fetal malformations has been associated with insulin use. Poor maternal glycemic control increases risks of congenital anomalies, macrosomia, neonatal hypoglycemia, and respiratory distress syndrome. Tight glycemic control is essential. |
■ FDA Black Box Warning
Hypoglycemia: Insulin therapy can cause severe hypoglycemia, which may lead to loss of consciousness, seizures, or death. Patient education on recognition and management of hypoglycemia is essential.
| Serious Effects |
["Hypoglycemia (absolute contraindication)","Hypersensitivity to regular insulin or any excipients in the formulation"]
| Precautions | ["Hypoglycemia: Most common adverse effect; adjust dose with changes in diet, exercise, or renal/hepatic function.","Hypokalemia: Insulin can cause rapid shift of potassium into cells; monitor potassium levels, especially in patients at risk for hypokalemia.","Allergic reactions: Local or systemic hypersensitivity reactions may occur.","Renal or hepatic impairment: May require dose adjustment due to altered clearance.","Medication errors: Do not confuse with other insulin formulations (e.g., NPH, analogs) due to differences in onset and duration."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood glucose levels frequently. Assess HbA1c every 1-2 months. Monitor for hypoglycemia and hyperglycemia. Fetal monitoring includes ultrasound for growth and anatomy, nonstress test, and biophysical profile as indicated for gestational diabetes or preexisting diabetes. |
| Fertility Effects | No known direct effects on fertility. Adequate glycemic control improves fertility outcomes in women with diabetes. |